INTRODUCTION

Th17 cells are a pro-inflammatory subset of CD4
+ effector T-cells characterised by the production of IL-17A/F, surface expression of C-C chemokine receptor (CCR)6 and lineage specific transcription factor RAR-related orphan rector (ROR)C [1] . Th17 cells predominantly reside at the mucosal surfaces where they play a pivotal role in inflammatory reactions and protective immunity against intra- [2] and extracellular [3] bacterial and fungal infections. An imbalance in Th17
proportion has been implicated in the pathogenesis of TB.
Approximately one third of the global population suffers from TB; a granulomatous disease spread by the airborne pathogen Mycobacterium tuberculosis (MTB). MTB cell wall component, trehalose-6-6'-dimycolate (TDM/cord factor) has been shown to induce the production of Th17 differentiating cytokines from antigen presenting cells through a the C-type lectin Mincle pathway [4] . Conflicting studies have noted an expansion of Th17/IL-17 axis in the peripheral blood and pleural fluid [5, 6] and a reduced frequency of Th17 cells in peripheral blood [7, 8] and bronchoalveolar lavage (BAL) fluid [7] during active MTB infection, with correlation to disease severity [5] .
HIV is the most powerful risk factor predisposing for active TB infection which remains the number one communicable HIV-related cause of death. In South Africa, approximately 62% of TB patients are HIV positive [9] . HIV infection is characterised by chronic immune activation and systemic depletion of CD4 + T-cells. The preferential loss of Th17 cells from the mucosa and 3 peripheral blood with reduced levels of IL-17 during HIV infection is well documented. This loss is not completely restored by antiretroviral therapy [10, 11] suggesting that HIV infection interferes in the generation of Th17 cells [12] .
Th17 lymphocytes are significant in the pathogenesis of TB and a potential predictor of disease severity; however, data on the proportion and role of Th17 cells in TB are conflicting. Furthermore, the confounding effect of HIV co-infection on Th17 frequency has not been investigated. Notably, 40-80% of HIV-related TB is extrapulmonary, the most common form being TB pleurisy [13] and the immunological mechanisms of which are not accurately reflected systemically [14] . Taken together with the mucosal predominance of Th17 cells, this study characterised the proportion of Th17 lymphocytes and the cytokine microenvironment in TB/HIV pleurisy in vitro and ex vivo.
METHODS
Study Population
This study protocol was approved by the institutional Biomedical Research Ethics Committee Table 1. 4 557815) (60min, RT, in the dark). Analysis was performed using the Accuri C6 flow cytometer (BD Biosciences, USA) and data analysed using FlowJo vX (10.0.7r2). Samples were run in triplicate and 30,000 events acquired. Antibodies were purchased from BD Biosciences, USA, with the exception of anti-RORC2 which was purchased from R&D Systems.
Molecular Profiling
Total RNA was extracted from PEMCs using Qiazol Lysis Reagent (Qiagen, USA) following an inhouse protocol. Briefly, cells were added to Qiazol Lysis Reagent (1:1) and incubated at RT (5min) and subsequently frozen (-80°C, overnight). Chloroform (200μl) was added, incubated at RT (3min) and centrifuged (8,200rpm , 15min, 4°C). Isopropanol (500μl) was added to the aqueous phase and frozen (-80°C, overnight). The samples were centrifuged (8,200rpm , 20min, 4°C) and the RNA pellet washed in cold ethanol (75%, 1ml). The samples were then centrifuged (6,400rpm, 15min, 4°C), the ethanol aspirated and the RNA pellet re-suspended in 15μl of nuclease free water. Total RNA was quantified on a Nanodrop™ 2000 UV-Vis Spectrophotometer (Thermoscientific, USA) and purity assessed using the A 260 /A 280 ratio.
Copy DNA (cDNA) was synthesised using the RT 2 First Strand Kit (catalogue number 330401, Qiagen, USA) according to the manufacturer's instructions. Briefly, 1μg of RNA pooled equally from 5 patients per group was added to a genomic DNA elimination mix (5 × gDNA elimination buffer, H 2 0) to a total volume of 10μl and incubated at 42°C (5min) followed by 4°C (1min).
Subsequently, reverse transcription mix (10μl, 5 × RT buffer 3, primer and external control mix, RT enzyme mix, H 2 0) was added and incubated at 42°C (15min) followed by 95°C (5min), on the GeneAmp® PCR System 9700 (Applied Biosystems, USA), to produce cDNA. 7 Real-time PCR was used to quantify STAT3, IL-6, IL-6R and IL-1β mRNA levels. A 25μl reaction consisted of 12.5μl RT 2 SYBRGreen Masterrmix (catalogue number 330500, Qiagen, United States), 8.5μl nuclease free water, 2μl cDNA and 1μl sense and anti-sense primers. Primer
The mRNA expression was compared and normalised to a housekeeping gene, 18S sense 5'-TAGAATTACCACAGTTATCC-3' antisense 5'-TAGAATTACCACAGTTATCC-3'. Cycling conditions were as follows: initial denaturation (95°C, 10min) followed by 40 cycles of denaturation (95°C, 30s), annealing (STAT3: 64°C, IL-6: 60°C, IL-6R: 60°C, IL-1β: 60°C for 30s) and extension (72°C, 1min) on a CFX Real-Time PCR Detector (Bio-Rad, USA).The quantification and melt curves were analysed using CFX Manager™ Software v3.0 (Bio-Rad, USA). The mRNA levels were calculated using the method described by Livak and Schmittgen (2001) [15] and is represented as fold changes and relative expression to the control. Samples were run in triplicate and the experiments were repeated twice.
Cytokine Profiling
Cytokine profiling was performed using the Bio- Briefly, standards and samples; PEF (1:6) and supernatant (1:3), were diluted in standard and sample diluent HB respectively. The beads (50μl) were added to the assay plate and washed twice (100μl wash buffer, Bio-Plex Pro™ Wash Station). Standards, samples and controls were added and incubated (50μl, 1h in the dark, RT, 350rpm). The plate was washed three times and incubated with detection antibody (25μl, 30min in the dark, RT, 350rpm). The plate was washed three times and incubated with Streptavidin-PE (50μl, 10min in the dark, RT, 350rpm). The plate was washed three times and the beads re-suspended in assay buffer (125μl, 30 seconds, in the dark, RT, 350rpm).
Data acquisition was performed on a Bio-Plex 200 and analysis was performed using Bio-Plex
Manager™ software v6.0. Standards and samples were run in duplicate. Results were analysed using a 5-paramter logistic regression constructed from recombinant protein standards. The results were normalised to the treatment and then compared between groups. 8 
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software (v5.0). (Figure 2 ). Since we found increased expression of mRNA transcripts related to Th17 polarisation in TB + HIV + PEMCs, we questioned whether in fact these were translated into secreted cytokine using a Bioplex multi-analyte cytokine screen. was observed, both of which are largely uncharacterised in TB and HIV infection (Figure 4 ).
DISCUSSION
The Th17/IL17 axis is suggested to provide protective immunity against MTB by contributing to development and organisation of the granuloma. Early expression of pulmonary IL-17 in primary infection is pivotal in cellular recruitment by inducing chemokine secretion from nonhaematopoietic cells. This predominantly results in neutrophil and CCR5 + lymphocyte recruitment, through the induction of IL-8 and chemokine C-X-C motif ligand (CXCL) 13 respectively, to form lung lymphoid follicles for optimal macrophage activation and bacterial clearance [16, 17] .
However, during the chronic stages of infection, Th17 hyperactivity can lead to immunopathology via IL-17-CXCL mediated influx of immune cells, breakdown of the granuloma, cavitation and transmission [18] . Th17 immunity has also been shown to contribute to mucosal TB vaccine immunity by IL-17A induction of CXCL13 [16] . However, there is no consensus on the proportion of Th17 cells in TB infection and the significance of this contribution to disease pathogenesis. 13 This is further confounded by HIV co-infection. Th17 cells show greater HIV susceptibility than other T-cell subsets. Th17 lymphocyte targeting has been correlated with a higher expression of HIV envelope receptors CD4, CXCR4, CCR5 and α4β7 and low levels of autocrine production of CCR5 ligands CCL3 and CCL4, resulting in higher gp120 binding [19] . This is associated with a significant impairment in the generation of Th17 cells from peripheral naïve CD4 + T-cells [11] . In addition, the over expression of negative regulators in Th17 differentiation (phosphatase SHP2, suppressor of cytokine signalling (SOCS) 3 and protein inhibitor of activated STAT3 (PIAS3)) have been linked to Th17 deficiency in a simian immunodeficiency virus (SIV) model [20] .
Notably, HIV-1 infected long-term non-progressors [10] preserve the Th17 subset in peripheral blood and mucosa.
In our study, a significantly lower proportion of CD4 phenotype and effector functions [23] . Despite the reduction in Th17 frequency, there was no significant difference in the concentrations of IL-6, IL-21, and IL-23 between the two groups both in vitro and ex vivo indicating that the reduced proportion of Th17 cells is not a result of decreased polarising cytokines. In support of this, previous studies have shown that HIV infection is characterised by high levels of TGF-β [24] , IL-6 [25] and IL-1 [12] suggesting that failure to generate Th17 cells is not due to a lack of promoting cytokines.
Notably, TB + HIV + pleurisy was associated with a significant 3.708 fold increase in IL-1β pleural fluid concentration and a 11.662 fold increase in IL-1β mRNA levels in PEMCs. Th17 cells express higher IL-1R levels than other CD4 subsets [26] , in turn IL-1β upregulates the expression of transcription factors IRF4 and RORC and acts synergistically with IL-6, IL-23 and TGF-β to stimulate Th17 differentiation and maintain IL-17A, IL-17F, IL-21 and IL-22 cytokine production in effector cells [22, 26] . Very recently, a clinical isolate of the hypervirulent W-Beijing strain of MTB has been shown to induce a potent IL-17 protective response in a murine model through the induction of dendritic cell IL-1β and the subsequent formation of lung lymphoid follicles [16] .
Furthermore, it was shown that blocking of IL-1/IL-1R signalling led to almost complete inhibition 14 of IL-17A production during MTB stimulation in PBMCs [27] . Our results indicate that Th17 lymphocytes in TB/HIV pleurisy may be defective in their ability to respond to IL-1β.
In the current study we found a 1.657 and 3.076 fold increase in IL-6R and IL-6 mRNA levels in co-infection, respectively but no increase in IL-6 cytokine levels in pleural fluid. This was interesting as recently the upregulation of IL-6 has been identified as a potential biomarker of mycobacterial infection in vitro [28] . During active TB infection IL-6 levels are increased in plasma and broncho-alveolar lavage (BAL) fluid with positive correlation to disease severity [29] .
Furthermore, IL-6 is noted to be elevated in all phases of HIV chronic infection and a clinical trial has shown that increased IL-6 levels are associated with increased all-cause mortality in HIV [30] .
Our findings suggest that post transcriptional regulation of key Th17 polarising cytokines may influence the cytokine microenvironment.
Despite a significant decrease in the frequency of Th17 cells in TB + HIV + pleurisy, there was no significant difference in the concentration of effector cytokines IL-17A and IL-17F between the two groups in vitro and ex vivo. In line with our findings, it has been observed that IL-17 mRNA levels in BAL cells of active TB patients and healthy controls do not differ significantly [31] . This may be a result of IL-17A production by CD8 + T-cells [32] , γöT-cells [33, 34] , natural killer cells [35] , neutrophils [36] and innate lymphoid cells [37] . The contribution of these different cell types to IL-17 associated diseases is still unknown [17] . γöT-cells, enriched at mucosal surfaces, such as the lung, have been indicated as a major source of early IL-17A production in response to MTB [33, 34] and found to be at significantly higher frequency in the peripheral blood of active TB patients compared to healthy donors [34] . γöT-cells can respond to IL-23 and IL-1β amplifying Th17 responses [33] and therefore it is possible that the IL-17 observed in TB + HIV + pleurisy may be a result of a IL-1β -γöT-cell pathway. [40] which is enhanced by TNF-α [41] . HIV-1 Tat protein induces production of TNF-α and IFN-γ in human monocytes/macrophages, in turn these cytokines synergistically stimulate HIV replication in vitro [42] . This suggests that in co-infection TNF-α and IFN-γ provide protective immunity against MTB but promote replication of HIV indicating that defence against one pathogen allows injury by another. Furthermore, IFN-γ has been shown to limit the size of the Th17 population during MTB infection [43] . been implicated in pathogenesis of TB [7, 44] and HIV [45] . However, it remains to be determined by other cell types, including innate lymphoid cells [46] . In this regard, during experimental MTB infection, IL-22 was found to be predominantly produced by Th1 and Th22 cells rather than Th17 cells [47] . IFN-γ suppresses PBMC IL-17A production and Th17 activity but not IL-22 production [7, 47] allowing for effective IL-22 production in the absence of Th17 cells, in line with our results.
The 3.055 fold increase in IL-31 concentration in TB + HIV + pleurisy is novel. IL-31 is generally associated with Th2 mediated skin inflammation or allergic responses in the airways and GIT and has not been characterised in TB/HIV co-infection or mono-infection. IL-31 mRNA is upregulated in the lungs after antigen challenge, the targets of which are primarily bronchial epithelial cells, pulmonary fibroblasts and macrophages where it upregulates pro-inflammatory cytokine and chemokine gene expression involved in cellular recruitment [48] , in the context of TB this may contribute to granuloma organisation. IL-31 can also directly inhibit IL-17A/F mRNA synthesis in Th17 cells through the regulation of PIAS molecules [49] possibly augmenting the observed decrease in Th17 frequency. 16 In HIV infection, the depletion of Th17 cells at the mucosal surface is associated with increased translocation of microbial into the systemic circulation rendering a patient more prone to opportunistic infections and suggested to be a predominant cause of chronic immune activation and HIV progression [12, 50] . At the respiratory mucosa, a loss of Th17 cells decreases mucosal defence to inhaled MTB and together with reduced IL-17-mediated cellular recruitment and granuloma organisation may result in the progression of active TB infection.
CONCLUDING REMARKS
A reduced proportion of Th17 cells were observed in TB + HIV + pleurisy independent of alteration in the levels of Th17 polarising cytokines and IL-17A/F effector cytokines in the localised microenvironment.
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